- Home
- NVCT vs OBIO Comparison
NVCT vs OBIO Comparison
Compare NVCT & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVCT
- OBIO
- Stock Information
- Founded
- NVCT 2020
- OBIO 2017
- Country
- NVCT United States
- OBIO United States
- Employees
- NVCT N/A
- OBIO N/A
- Industry
- NVCT Medicinal Chemicals and Botanical Products
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- NVCT Health Care
- OBIO Health Care
- Exchange
- NVCT Nasdaq
- OBIO Nasdaq
- Market Cap
- NVCT 167.0M
- OBIO 147.8M
- IPO Year
- NVCT 2022
- OBIO N/A
- Fundamental
- Price
- NVCT $6.40
- OBIO $2.73
- Analyst Decision
- NVCT Strong Buy
- OBIO Strong Buy
- Analyst Count
- NVCT 3
- OBIO 4
- Target Price
- NVCT $15.33
- OBIO $14.00
- AVG Volume (30 Days)
- NVCT 75.1K
- OBIO 303.5K
- Earning Date
- NVCT 11-04-2025
- OBIO 08-12-2025
- Dividend Yield
- NVCT N/A
- OBIO N/A
- EPS Growth
- NVCT N/A
- OBIO N/A
- EPS
- NVCT N/A
- OBIO N/A
- Revenue
- NVCT N/A
- OBIO $2,944,000.00
- Revenue This Year
- NVCT N/A
- OBIO $19.83
- Revenue Next Year
- NVCT N/A
- OBIO $12.53
- P/E Ratio
- NVCT N/A
- OBIO N/A
- Revenue Growth
- NVCT N/A
- OBIO 41.61
- 52 Week Low
- NVCT $4.44
- OBIO $2.37
- 52 Week High
- NVCT $11.80
- OBIO $6.50
- Technical
- Relative Strength Index (RSI)
- NVCT 44.54
- OBIO 49.24
- Support Level
- NVCT $6.32
- OBIO $2.65
- Resistance Level
- NVCT $6.90
- OBIO $3.08
- Average True Range (ATR)
- NVCT 0.34
- OBIO 0.16
- MACD
- NVCT 0.05
- OBIO 0.02
- Stochastic Oscillator
- NVCT 36.71
- OBIO 50.00
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.